rabeprazole

(redirected from Pariet)
Also found in: Dictionary.
Related to Pariet: Rabeprazole

rabeprazole

 [rah-bep´rah-zōl]
an inhibitor of stomach hydrochloric acid secretion administered orally as the sodium salt in treatment of gastroesophageal reflux disease and similar conditions marked by excessive acid.

rabeprazole

/ra·bep·ra·zole/ (rah-bep´rah-zōl) a proton pump inhibitor used as the sodium salt to inhibit gastric acid secretion in the treatment of gastroesophageal reflux disease and conditions marked by excessive secretion of gastric acid.

rabeprazole

a proton pump inhibitor.
indications Rabeprazole is used to treat gastroesophageal reflux disease (GERD), severe erosive esophagitis, poorly responsive systemic GERD, pathological hypersecretory conditions such as Zollinger-Ellison syndrome, systemic mastocytosis, multiple endocrine adenomas, and active duodenal ulcers.
contraindication Known hypersensitivity to this drug prohibits its use.
adverse effects Life-threatening effects are proteinuria, hematuria, pancytopenia, thrombocytopenia, neutropenia, and leukocytosis. Other adverse effects include abdominal swelling, anorexia, irritable colon, esophageal candidiasis, epistaxis, urticaria, alopecia, hypoglycemia, increased hepatic enzymes, weight gain, tinnitus, angina, tachycardia, bradycardia, palpitations, peripheral edema, urinary tract infection, increased creatinine, testicular pain, glycosuria, and fever. Common side effects include headache, dizziness, asthenia, diarrhea, abdominal pain, vomiting, nausea, constipation, flatulence, acid regurgitation, upper respiratory infections, cough, rash, and back pain.

rabeprazole

Aciphex® GI disease A proton pump inhibitor used to manage for heartburn, duodenal ulcers, gastric ulcers, GERD, hypersecretory conditions–eg, Zollinger-Ellison syndrome. See GERD.
References in periodicals archive ?
Scheduled for production: Methycobal, Aricept, Pariet and other products
Both Eisai and Zeria have a strong track record in the field of gastrointernal diseases (Eisai with the PPI Pariet and the gastritis / gastric ulcer treatment Selbex, Zeria with the ulcerative colitis treatment Asacol and the world's first functional dyspepsia treatment Acofide) and will conduct co-promotional activities with the aim of bringing a product to the market for acid related diseases as soon as possible.
pylori eradication triple therapy with Pariet and two antimicrobial agents, successful eradication significantly depends on whether the patient properly adheres to the prescribed treatment regimen.
Pariet is a proton pump inhibitor discovered and developed by Eisai.
Currently approved in more than 100 countries and territories worldwide, Pariet was first launched in Japan in 1997, where it is indicated for multiple uses, including for the treatment of gastric ulcer, duodenal ulcer, reflux esophagitis, non-erosive gastroesophageal reflux disease, and as an adjunct therapy in various types of Helicobacter pylori (H.
The authorization approves Rabecure Pack 400 and Rabecure Pack 800, which package together individual blister sheets each containing a daily triple formulation dose of Pariet, amoxicillin hydrate and clarithromycin for primary H.
During eradication therapy consisting of Pariet and two antimicrobial agents, the success of therapy depends on whether or not patients properly adhere to the prescribed treatment regimen.
markets for Aricept, a medicine for Alzheimer's disease, and Pariet, an ulcer medicine.
PARIET has clinically shown a rapid onset of action and a stable inhibitory effect on acid secretion with the approved indications in Japan including stomach ulcers, duodenal ulcers, reflux esophagitis, and as an adjunctive treatment for eradication of Helicobacter pylori bacteria in gastric/duodenal ulcers.
From April to September 2005, Eisai's net sales were 282,629 million yen, an 8% increase over the previous fiscal year's interim period, due to a rise in sales of Aricept (+18% to 89,991 million yen) and Pariet (+10% to 71,576 million yen).
From April to September 2005, Eisai's net sales were 282,629 Yen million, an 8% increase over the previous fiscal year's interim period, due to a rise in sales of Aricept (+18% to 89,991 Yen million) and Pariet (+10% to 71,576 Yen million).
Under the agreement, Snyder Healthcare Services will support Janssen and Eisai's launch of the new Pariet proton pump inhibitor in the US, the UK, Germany and France.